Back to results
US 12,723,071 B2Granted
Fusion constructs and uses thereof
AssigneeB-Portal Biologics, Inc.
InventorDaniel Chain
Life of this patent
Estimating the term…
Abstract
Fusion constructs are described. A fusion construct contains a peptide of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 28, fused to a peptide or protein (e.g., an antibody). As compared to the peptide or protein, fusion constructs exhibits improved penetration through the BBB, and are released on the abluminal surface of the BBB, after the post-luminal surface uptake. Fusion constructs could be used in drug discovery, diagnosis, prevention and treatment of diseases.
Claims17
A fusion construct of Formula I:
- M-L-C (Formula I),
- wherein M is selected from the group consisting of antibodies, pronectins, affibodies, affilins, anticalins, atrimers, avimers, DARPins, fynomers, bicyclic peptides, and non-antibody proteins,
- L is an optional linker, and
- C is a peptide comprising SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, or SEQ ID NO:
- 28,
- wherein the non-antibody proteins are therapeutic proteins, and
- the antibodies comprise (a) a heavy chain variable region comprising CDR1 represented by sequence GFTFNTYA (SEQ ID NO:
- 7), CDR2 represented by IRSKSNNYAT (SEQ ID NO:
- 8), and CDR3 represented by VGGGDF (SEQ ID NO:
- 9);
- and (b) a light chain variable region comprising CDR1 represented by sequence QEISVY (SEQ ID NO:
- 10), CDR2 represented by sequence GAF (SEQ ID NO:
- 11), and CDR3 represented by sequence LQYVRYPWT (SEQ ID NO:
- 12).
15 more elements
A fusion construct of Formula I:
- M-L-C (Formula I),
- wherein M is an antibody,
- L is an optional linker, and
- C is a peptide comprising SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, or SEQ ID NO:
- 28, and
- the antibody comprises (a) a heavy chain variable region comprising CDR1 represented by sequence GFTFNTYA (SEQ ID NO:
- 7), CDR2 represented by IRSKSNNYAT (SEQ ID NO:
- 8), and CDR3 represented by VGGGDF (SEQ ID NO:
- 9);
- and (b) a light chain variable region comprising CDR1 represented by sequence QEISVY (SEQ ID NO:
- 10), CDR2 represented by sequence GAF (SEQ ID NO:
- 11), and CDR3 represented by sequence LQYVRYPWT (SEQ ID NO:
- 12).
14 more elements
A fusion construct of Formula I:
- M-L-C (Formula I),
- wherein M is an antibody,
- L is a linker, and
- C is a peptide comprising SEQ ID NO:
- 2, and
- the antibody comprises (a) a heavy chain variable region comprising CDR1 represented by sequence GFTFNTYA (SEQ ID NO:
- 7), CDR2 represented by IRSKSNNYAT (SEQ ID NO:
- 8), and CDR3 represented by VGGGDF (SEQ ID NO:
- 9);
- and (b) a light chain variable region comprising CDR1 represented by sequence QEISVY (SEQ ID NO:
- 10), CDR2 represented by sequence GAF (SEQ ID NO:
- 11), and CDR3 represented by sequence LQYVRYPWT (SEQ ID NO:
- 12).
10 more elements
Dependencies are inferred from the claim text.